Medtide (FRA:FQ2) Marketable Securities: €22.69 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FQ2 Medtide Inc FRA:FQ2
31 GF Score
Price €2.18
View Full Analysis

What is Medtide Marketable Securities?

Medtide FRA:FQ2 -6.03% 31 Marketable Securities is €22.69 Mil as of Dec. 2025. GuruFocus rates FRA:FQ2 with a GF Score™ of 31/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Medtide's Marketable Securities for the quarter that ended in Dec. 2025 was €22.69 Mil.

Medtide's annual Marketable Securities increased from Dec. 2023 (€14.14 Mil) to Dec. 2024 (€18.76 Mil) and increased from Dec. 2024 (€18.76 Mil) to Dec. 2025 (€22.69 Mil).

Medtide  (FRA:FQ2) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Medtide Marketable Securities Related Terms

Medtide Marketable Securities Historical Data

* Premium members only.

The historical data trend for Medtide's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtide Marketable Securities Chart

Medtide Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
15.65 46.33 14.14 18.76 22.69

Medtide Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only 14.27 18.76 17.46 22.69 29.08
FRA:FQ2
31GF Score
Medtide Inc FRA:FQ2
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtide Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €22.69 Mil mean?
Medtide (FRA:FQ2) has a Marketable Securities of €22.69 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Medtide and its competitors.
Is Medtide's Marketable Securities too high?
Medtide's current Marketable Securities is €22.69 Mil. Overall, Medtide has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's Marketable Securities compare to VRTX and REGN?
Medtide's Marketable Securities of €22.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Medtide and its competitors. Medtide's current Marketable Securities is €22.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (FRA:FQ2) has a current Marketable Securities of €22.69 Mil. The current Marketable Securities is €22.69 Mil. Medtide's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Medtide (FRA:FQ2), the current Marketable Securities is €22.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medtide Business Description

Other Exchanges 03880:Hong Kong
Address No. 69, 12 Street, Qiantang District, Zhejiang, Hangzhou, CHN
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
31GF Score

Get the complete analysis for FRA:FQ2

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.18
Price